CALCULATION OF REVENUE FROM COLLABORATION AGREEMENT(In thousands, unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2010200920102009Nexavar product revenue, net (as recorded by Bayer)$ 226,181$ 229,243$ 676,665$ 608,295Nexavar revenue subject to profit sharing (as recorded by Bayer)$ 191,553$ 199,774$ 580,399$ 548,093Combined cost of goods sold, distribution, selling, general and administrative expenses78,46476,309237,184222,531Combined collaboration commercial profit$ 113,089$ 123,465$ 343,215$ 325,562Onyx's share of collaboration commercial profit$ 56,545$ 61,732$ 171,607$ 162,781Reimbursement of Onyx's shared marketing expenses4,7275,34217,02616,079Royalty revenue2,4242,0636,7394,214Revenue from collaboration agreement$ 63,696$ 69,137$ 195,372$ 183,074ONYX PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME (LOSS)(In thousands, except per share amounts)
(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2010200920102009GAAP net income (loss)
21,672Non-GAAP adjustments:Contingent consideration
5,622-101,107-Employee stock-based compensation
5,8744,97216,59214,933Imputed interest related to the convertible senior notes due 2016
2,2921,0276,6711,027Acquisition related transaction costs
-7,000-7,000Non-GAAP net income (3)$
45,643Computation of non-GAAP diluted net income (loss)Non-GAAP net income (3)$
45,643Add:Interest and issuance costs related to dilutive convertible senior notes (4)2,5321,228-1,228Non-GAAP net income - diluted (3)$
46,871Computation of non-GAAP diluted sharesBasic shares
62,70760,24862,56258,201Dilutive effect of optio
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved